Compare JOF & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JOF | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | 301.7M |
| IPO Year | 1996 | 1996 |
| Metric | JOF | LCTX |
|---|---|---|
| Price | $12.63 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 70.7K | ★ 839.2K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $9.95 | $1.00 |
| 52 Week High | $12.76 | $2.09 |
| Indicator | JOF | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 53.23 |
| Support Level | $12.13 | $1.02 |
| Resistance Level | $12.72 | $1.18 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 90.09 | 68.62 |
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.